<!DOCTYPE html><html><head><title>Parkinson's disease: percentage of visits for patients with a diagnosis of Parkinson's disease where patients (or caregiver[s], as appropriate) were queried about Parkinson's disease medication-related motor complications (e.g., wearing-off, dyskinesia, or off-time).</title><link rel="stylesheet" type="text/css" href="style.css"></head><body><div class='section'>
<h2>General
</h2>
<div class='field field_text'>
<h3>
Title
</h3>
<div class='FieldValue'>
<div class="content_title">Parkinson's disease: percentage of visits for patients with a diagnosis of Parkinson's disease where patients (or caregiver[s], as appropriate) were queried about Parkinson's disease medication-related motor complications (e.g., wearing-off, dyskinesia, or off-time).</div>
</div>

</div>
<div class='field field_citation'>
<h3>
Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>American Academy of Neurology (AAN). Parkinson's disease physician performance measurement set. St. Paul (MN): American Academy of Neurology (AAN); 2009 Dec 16. 45 p. </td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Cheng EM, Tonn S, Swain-Eng R, Factor SA, Weiner WJ, Bever CT Jr, American Academy of Neurology Parkinson Disease Measure Development Panel. Quality improvement in neurology: AAN Parkinson disease quality measures: report  of the Quality Measurement and Reporting Subcommittee of the American Academy of  Neurology. Neurology. 2010 Nov 30;75(22):2021-7. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=21115958" target="_blank">PubMed</a></td></tr></table>
</div>

</div>

</div>
<div class='section'>
<h2>Measure Domain
</h2>
<div class='field field_picklist-one'>
<h3>
Primary Measure Domain
</h3>
<div class='FieldValue'>
Clinical Quality Measures: Process
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Secondary Measure Domain
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>

</div>
<div class='section'>
<h2>Brief Abstract
</h2>
<div class='field field_text'>
<h3>
Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This measure is used to assess the percentage of visits for patients with a diagnosis of Parkinson's disease where patients (or caregiver[s], as appropriate) were queried about Parkinson's disease medication-related motor complications (e.g., wearing off, dyskinesia, or off-time).</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Rationale
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Dopaminergic therapies are commonly accompanied by motor fluctuations, including off time (periods of return of Parkinson's disease [PD] symptoms when medication effect wears off) and dyskinesia (drug-induced involuntary movements, including chorea and dystonia) in most patients. It is important to query patients about these problems because medication adjustments and the addition of adjunctive medications can often ameliorate the problem(s). With these adjustments, the patient's quality of life can be improved.*</p>
<p class="Note">*The following clinical recommendation statements are quoted <span style="text-decoration: underline;">verbatim</span> from the referenced clinical guidelines and represent the evidence base for the measure:</p>
<p class="Note">Monoamine oxidase isoenzyme type B (MAO-B) inhibitors may be used to reduce motor fluctuations in people with later PD. (Level A) (NICE GL35, Jun 2006)</p>
<p class="Note">Catechol-O-methyltransferase (COMT) inhibitors may be used to reduce motor fluctuations in people with later PD. (Level B) (NICE GL35, Jun 2006)</p>
<p class="Note">Modified-release levodopa preparations may be used to reduce motor complications in people with later PD, but should not drugs of first choice. (Level A) (NICE GL35, Jun 2006)</p>
<p class="Note">Dopamine agonists may be used to reduce motor fluctuations in people with later PD. (Level A) (NICE GL35, Jun 2006)</p>
<p class="Note">Wearing-Off</p>
<ul style="list-style-type: disc;" class="Note">
    <li>Adjust levodopa dosing. In an early phase, when motor fluctuations are just becoming apparent, adjustments in the frequency of levodopa dosing during the day, tending to achieve four to six daily doses, might attenuate the wearing-off. (Good Practice Point) (EFNS PD Part II, Nov 2006) </li>
    <li>Switch from standard levodopa to controlled release (CR) formulation. CR formulations of levodopa can also improve wearing-off. (Level C) (EFNS PD Part II, Nov 2006) </li>
    <li>Add COMT inhibitors or MAO-B inhibitors. No recommendations can be made on which treatment should be chosen first - on average, all reduce OFF time by about 1 to 1.5 h/day. The only published direct comparison (Level A) showed no difference between entacapone and rasagiline. (EFNS PD Part II, Nov 2006) </li>
    <li>Add dopamine agonists. Oral dopamine agonists are efficacious in reducing OFF time in patients experiencing wearing-off. Currently, no dopamine agonist has proven better than another, but switching from one agonist to another can be helpful in some patients. (Level B/C) (EFNS PD Part II, Nov 2006) </li>
    <li>Add amantadine or an anticholinergic. In patients with disabling recurrent OFF symptoms that fail to improve further with the above mentioned strategies, the addition of an anticholinergic (in younger patients), or amantadine, may improve symptoms in some cases. (Good Practice Point) (EFNS PD Part II, Nov 2006) </li>
</ul>
<p class="Note">Peak-Dose Dyskinesia</p>
<ul style="list-style-type: disc;" class="Note">
    <li>Add amantadine - most studies use 200 to 400 mg/day. The benefit may last &lt;8 months. (Level A) (EFNS PD Part II, Nov 2006) </li>
    <li>Reduce individual levodopa dose size, at the risk of increasing OFF time. The latter can be compensated for by increasing the number of daily doses of levodopa or increasing the doses of a dopamine agonist. (Level C) (EFNS PD Part II, Nov 2006) </li>
    <li>Discontinue or reduce dose of MAO-B inhibitors or COMT inhibitors at the risk of worsening wearing-off. (GPP) (EFNS PD Part II, Nov 2006) </li>
    <li>Add atypical antipsychotics, clozapine with doses ranging between 12.5 and 75 mg/day up to 200 mg/day. (Level A) (EFNS PD Part II, Nov 2006) </li>
    <li>Add quetiapine. (Level C) (EFNS PD Part II, Nov 2006) </li>
    <li>Amantadine may be considered to reduce dyskinesia. (Level C) (AAN QSS PD Dyskin, Apr 2006) </li>
    <li>Entacapone and rasagiline should be offered to reduce off time. (Level A) (AAN QSS PD Dyskin, Apr 2006) </li>
    <li>Pergolide, pramipexole, ropinirole, and tolcapone should be considered to reduce off time. (Level B) (AANQSS PD Dyskin, Apr 2006) </li>
    <li>Apomorphine, cabergoline, and selegiline may be considered to reduce off time. (Level C) (AAN QSS PD Dyskin, Apr 2006) </li>
    <li>The available evidence does not establish superiority of one medicine over another in reducing off time. (Level B) (AAN QSS PD Dyskin, Apr 2006) </li>
</ul></div>
</div>

</div>
<div class='field field_citation'>
<h3>
Evidence for Rationale
</h3>
<div class='FieldValue'>
<table><tr><td>American Academy of Neurology (AAN). Parkinson's disease physician performance measurement set. St. Paul (MN): American Academy of Neurology (AAN); 2009 Dec 16. 45 p. </td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, Larsen JP, Lees A, Oertel W, Poewe W, Rascol O, Sampaio C, European Federation of Neurological Societies, Movement Disorder Society-European Section. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the EFNS and the MDS-ES. Part II: late (complicated) Parkinson's disease. Eur J Neurol. 2006 Nov;13(11):1186-202. [196 references] <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=17038032" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, Larsen JP, Lees A, Oertel W, Poewe W, Rascol O, Sampaio C, European Federation of Neurological Societies, Movement Disorder Society-European Section. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol. 2006 Nov;13(11):1170-85. [190 references] <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=17038031" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>National Collaborating Centre for Chronic Conditions. Parkinson's disease. National clinical guideline for diagnosis and management in primary and secondary care. London (UK): Royal College of Physicians; 2006. 237 p.  [418 references]</td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ, Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr 11;66(7):983-95. [59 references] <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16606909" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ, Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr 11;66(7):968-75. [47 references] <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16606907" target="_blank">PubMed</a></td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Primary Health Components
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Parkinson's disease; querying of patient/caregiver; medication-related motor complications (wearing-off, dyskinesia, off-time)</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Denominator Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>All visits for patients with a diagnosis of Parkinson's disease (see the related "Denominator Inclusions/Exclusions" field)</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Numerator Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Patient visits with patient (or caregiver[s], as appropriate) queried about Parkinson's disease medication-related motor complications (e.g., wearing-off, dyskinesia, or off-time) (see the related "Numerator Inclusions/Exclusions" field)</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Evidence Supporting the Measure
</h2>
<div class='field field_picklist-choice'>
<h3>
Type of Evidence Supporting the Criterion of Quality for the Measure
</h3>
<div class='FieldValue'>
A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence
</div>
<div class='FieldValue'>
One or more research studies published in a National Library of Medicine (NLM) indexed, peer-reviewed journal
</div>

</div>
<div class='field field_text'>
<h3>
Additional Information Supporting Need for the Measure
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Extent of Measure Testing
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>State of Use of the Measure
</h2>
<div class='field field_picklist-one'>
<h3>
State of Use
</h3>
<div class='FieldValue'>
Current routine use
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Current Use
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>

</div>
<div class='section'>
<h2>Application of the Measure in its Current Use
</h2>
<div class='field field_picklist-choice'>
<h3>
Measurement Setting
</h3>
<div class='FieldValue'>
Ambulatory/Office-based Care
</div>
<div class='FieldValue'>
Skilled Nursing Facilities/Nursing Homes
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Professionals Involved in Delivery of Health Services
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Least Aggregated Level of Services Delivery Addressed
</h3>
<div class='FieldValue'>
Individual Clinicians or Public Health Professionals
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Statement of Acceptable Minimum Sample Size
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>
<div class='field field_text'>
<h3>
Target Population Age
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Target Population Gender
</h3>
<div class='FieldValue'>
Either male or female
</div>

</div>

</div>
<div class='section'>
<h2>National Strategy for Quality Improvement in Health Care
</h2>
<div class='field field_text'>
<h3>
National Quality Strategy Aim
</h3>
<div class='FieldValue'>
<ul><li>Better Care</li></ul>
</div>

</div>
<div class='field field_text'>
<h3>
National Quality Strategy Priority
</h3>
<div class='FieldValue'>
<ul><li>Prevention and Treatment of Leading Causes of Mortality</li></ul>
</div>

</div>

</div>
<div class='section'>
<h2>Institute of Medicine (IOM) National Health Care Quality Report Categories
</h2>
<div class='field field_picklist-choice'>
<h3>
IOM Care Need
</h3>
<div class='FieldValue'>
Living with Illness
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
IOM Domain
</h3>
<div class='FieldValue'>
Effectiveness
</div>

</div>

</div>
<div class='section'>
<h2>Data Collection for the Measure
</h2>
<div class='field field_text'>
<h3>
Case Finding Period
</h3>
<div class='FieldValue'>
<div class="content_para"><p>At least once per year</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Denominator Sampling Frame
</h3>
<div class='FieldValue'>
Patients associated with provider
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Denominator (Index) Event or Characteristic
</h3>
<div class='FieldValue'>
Clinical Condition
</div>
<div class='FieldValue'>
Encounter
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Denominator Time Window
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_text'>
<h3>
Denominator Inclusions/Exclusions
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Inclusions</strong><br />
All visits for patients with a diagnosis of Parkinson's disease</p>
<p><strong>Exclusions</strong><br />
Documentation of medical reason for not querying patient (or caregiver[s], as appropriate) about Parkinson's disease medication-related motor complications (e.g., patient is not on a Parkinson's disease medication; patient is unable to respond and no informant is available)</p>
<p class="Note"><strong>Note</strong>: Refer to the original measure documentation for administrative codes.</p></div>
</div>

</div>
<div class='field field_picklist-choice-4'>
<h3>
Exclusions/Exceptions
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_text'>
<h3>
Numerator Inclusions/Exclusions
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Inclusions</strong><br />
Patient visits with patient (or caregiver[s], as appropriate) queried about Parkinson's disease medication-related motor complications (e.g., wearing-off, dyskinesia, or off-time)</p>
<p class="Note"><strong>Note</strong>: Refer to the original measure documentation for administrative codes.</p>
<p><strong>Exclusions</strong><br />
Unspecified</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Numerator Search Strategy
</h3>
<div class='FieldValue'>
Encounter
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Data Source
</h3>
<div class='FieldValue'>
Administrative clinical data
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Type of Health State
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>
<div class='field field_text'>
<h3>
Instruments Used and/or Associated with the Measure
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Computation of the Measure
</h2>
<div class='field field_picklist-one'>
<h3>
Measure Specifies Disaggregation
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Scoring
</h3>
<div class='FieldValue'>
Rate/Proportion
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Interpretation of Score
</h3>
<div class='FieldValue'>
Desired value is a higher score
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Allowance for Patient or Population Factors
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Standard of Comparison
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>

</div>
<div class='section'>
<h2>Identifying Information
</h2>
<div class='field field_text'>
<h3>
Original Title
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Measure #9: querying about Parkinson's disease medication-related motor complications.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Collection Name
</h3>
<div class='FieldValue'>
Parkinson's Disease Physician Performance Measurement Set
</div>

</div>
<div class='field field_orglist'>
<h3>
Submitter
</h3>
<div class='FieldValue'>
American Academy of Neurology - Medical Specialty Society
</div>

</div>
<div class='field field_orglist-p'>
<h3>
Developer
</h3>
<div class='FieldValue'>
American Academy of Neurology - Medical Specialty Society
</div>

</div>
<div class='field field_text'>
<h3>
Funding Source(s)
</h3>
<div class='FieldValue'>
<div class="content_para"><p>American Academy of Neurology</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Composition of the Group that Developed the Measure
</h3>
<div class='FieldValue'>
<div class="content_para"><p><em>Co-Chairs</em>: William Weiner, MD, FAAN; Stewart Factor, DO, FAAN</p>
<p><em>Expert Panel Facilitators</em>: Christopher Bever Jr., MD, MBA, FAAN; Eric M. Cheng, MD, MS</p>
<p><em>American Parkinson's Disease Association</em>: Michele Popadynec, RN</p>
<p><em>National Parkinson Foundation</em>: Joyce Oberdorf, MA</p>
<p><em>Parkinson's Disease Foundation</em>: Jim Beck, PhD</p>
<p><em>American Academy of Family Physicians</em>: H. James Brownlee Jr., MD</p>
<p><em>American Academy of Neurology</em>: Lisa Shulman, MD, FAAN; Sotirios A. Parashos, MD, PhD; Helen Bronte-Stewart, MD, FAAN; Janis Miyasaki, MD, FAAN; Marian Evatt, MD</p>
<p><em>American Association of Neurosurgeons/Congress of Neurological Surgeons</em>: Karl Sillay, MD</p>
<p><em>American Neurological Association</em>: Blair Ford, MD, FAAN</p>
<p><em>American Psychological Association</em>: Paul Moberg, PhD, ABPP/CN</p>
<p><em>American Psychiatric Association</em>: Laura Marsh, MD</p>
<p><em>Movement Disorder Society</em>: Daniel Tarsy, MD, FAAN</p>
<p><em>National Academy of Neuropsychology</em>: Alexander Tr&ouml;ster, PhD</p>
<p><em>Coding Specialists</em>: Marc Nuwer, MD, PhD, FAAN; Mustafa Saad Siddiqui, MD</p>
<p><em>Insurance Representatives</em>: Robert M. Kropp, MD, MBA, Aetna, Inc.; Wesley B. Wong MD, MMM, Anthem Blue Cross and Blue Shield; Monte Masten, MD, Humana, Inc.; David Stumpf, MD, UnitedHealth Group, Inc.</p>
<p><em>Methodologist</em>: Rebecca Kresowik</p>
<p><em>American Academy of Neurology Staff</em>: Rebecca Swain-Eng, MS; Sarah Tonn, MPH</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Financial Disclosures/Other Potential Conflicts of Interest
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Dr. Cheng serves as a consultant for the National Parkinson Foundation and receives research support from the NIH/NINDS (K23NS058571 [PI]), the VA Parkinson's Disease Research, Education, and Clinical Center, the Department of Veterans Affairs, the California Office of Statewide Planning and Development, the National Multiple Sclerosis Society, and the American Heart Association.</p>
<p>Ms. Tonn is a full-time employee of the American Academy of Neurology (AAN) and served as project director for AAN grants from Pfizer Inc. and the CDC.</p>
<p>Ms. Swain-Eng is a full-time employee of the AAN.</p>
<p>Dr. Factor has served on scientific advisory boards for Lundbeck Inc., Allergan, Inc., and UCB; serves as a section editor for <em>Current Treatment Options in Neurology</em>; receives royalties from the publication of <em>Parkinson's Disease Diagnosis and Clinical Management</em> (Demos, 2008) and <em>Drug Induced Movement Disorders</em> (Blackwell Futura, 2005); has given expert testimony, prepared affidavits, and served as a consultant for Boehringer Ingelheim; and receives research support from Teva Pharmaceutical Industries Ltd., Ipsen, UCB, and Schering-Plough Corp.</p>
<p>Dr. Weiner has served on scientific advisory boards for Santhera Pharmaceuticals and Rexahn Pharmaceuticals, Inc.; serves on the editorial boards of <em>Parkinsonism and Related Disorders</em> and <em>Neurological Reviews</em>, and as Editor of <em>Treatment Options in Neurology</em>; receives royalties from the publication of <em>Neurology for the Non-Neurologist</em> (6th edition, Kluwer/Lippincott 2010), <em>Parkinson's Disease: A Complete Guide for Patients and Family</em> (Hopkins University Press 2nd edition, 2007), and <em>Handbook of Clinical Neurology Hyperkinetic Disorders</em> (Elsevier, 2011); has received honoraria from Santhera Pharmaceuticals and Novartis; has received research support from Novartis, Santhera Pharmaceuticals, Boehringer Ingelheim, and has provided expert testimony and served as a subject matter expert in legal proceedings.</p>
<p>Dr. Bever serves on the editorial board of the <em>MS Quarterly Report</em>; is listed as a co-inventor on and receives royalties from Abraxis BioScience, Inc. for a pending patent regarding use of hematogenous stem cells in neuronal replacement therapy and gene delivery; receives royalties from the publication of <em>Ambulatory Medicine</em> (Lippincott Williams &amp; Wilkins, 7th edition, 2006); and has received research support from the Department of Veterans Affairs and the National MS Society.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Adaptation
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This measure was not adapted from another source.</p></div>
</div>

</div>
<div class='field field_date'>
<h3>
Date of Most Current Version in NQMC
</h3>
<div class='FieldValue'>
2009 Dec
</div>

</div>
<div class='field field_text'>
<h3>
Measure Maintenance
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This measurement set will be revised periodically with an extensive review every 3 years.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Date of Next Anticipated Revision
</h3>
<div class='FieldValue'>
<div class="content_para"><p>2012 Dec</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This is the current release of the measure.</p>
<p>The measure developer reaffirmed the currency of this measure in April 2016.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Availability
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Source available from the <a href="https://www.aan.com/uploadedFiles/Website_Library_Assets/Documents/3.Practice_Management/2.Quality_Improvement/1.Quality_Measures/1.All_Measures/parkinsons.pdf" title="American Academy of Neurology Web site">American Academy of Neurology (AAN) Web site</a>.</p>
<p>For more information, contact AAN at 201 Chicago Avenue, Minneapolis, MN 55415; Phone: 800-879-1960; Fax: 612-454-2746; Web site: <a href="http://www.aan.com" title="AAN Web site">www.aan.com</a>.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
NQMC Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NQMC summary was completed by ECRI Institute on December 16, 2011. The information was verified by the measure developer on January 30, 2012. </p>
<p>The information was reaffirmed by the measure developer on April 15, 2016.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Copyright Statement
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NQMC summary is based on the original measure, which is subject to the measure developer's copyright restrictions.</p>
<p>&copy; American Academy of Neurology.</p>
<p>The AAN does not directly or indirectly practice medicine or dispense medical services. The AAN assumes no liability for data contained or not contained herein.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Production
</h2>
<div class='field field_citation'>
<h3>
Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>American Academy of Neurology (AAN). Parkinson's disease physician performance measurement set. St. Paul (MN): American Academy of Neurology (AAN); 2009 Dec 16. 45 p. </td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Cheng EM, Tonn S, Swain-Eng R, Factor SA, Weiner WJ, Bever CT Jr, American Academy of Neurology Parkinson Disease Measure Development Panel. Quality improvement in neurology: AAN Parkinson disease quality measures: report  of the Quality Measurement and Reporting Subcommittee of the American Academy of  Neurology. Neurology. 2010 Nov 30;75(22):2021-7. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=21115958" target="_blank">PubMed</a></td></tr></table>
</div>

</div>

</div>
<div class='section'>
<h2>Disclaimer
</h2>
<div class='field field_text'>
<h3>
NQMC Disclaimer
</h3>
<div class='FieldValue'>
<p>The National Quality Measures Clearinghouseâ„¢ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.</p> 
<p>All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.</p> 
<p>Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the <a href="/help-and-about/summaries/inclusion-criteria">NQMC Inclusion Criteria</a>.</p> 
<p>NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding measure content are directed to contact the measure developer.</p>
</div>

</div>

</div>
</body></html>